Full-Time

Senior Director

Global Professional Education

Updated on 8/13/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

No salary listed

Tempe, AZ, USA

In Person

Master's, MBA, PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • Previous experience working in education for medical devices.
  • At least 10 years of progressive leadership or management experience in Medical Professional Affairs.
  • Experience leading professional strategy and key tactics for new product launch readiness, including market seeding, key opinion leader and advocate engagement, podium opportunities, and key educational initiatives.
  • Experience leading delivery of global or regional educational training strategies for healthcare professionals, internal proctors, non-physician proctors, and internal clinical staff.
  • Experience implementing education plans, strategies, global practices, policies, and processes for medical education programs, including field clinical, physician proctor, non-physician proctor, and fellows' programs.
  • Ability to continuously evaluate the internal and external environment to deliver novel medical education and training approaches, practices, and processes that improve efficiency and effectiveness.
  • Demonstrated leadership incorporating innovative approaches into professional education strategy and education materials.
  • Experience partnering with multiple internal and external stakeholders to deliver the business strategy.
  • Demonstrated leadership focused on hiring, developing, and retaining a world-class team and driving results.
  • Excellent written and verbal communication skills, including the ability to communicate effectively at all organizational levels.
  • In-depth understanding of clinical practices, especially procedures related to peripheral intervention devices.
  • Familiarity with current medical device technology and its applications.
  • Experience developing and implementing effective training programs for medical professionals.
  • Knowledge of healthcare regulations and standards to ensure training programs meet legal requirements.
  • Ability to lead and inspire a team in a collaborative and innovative environment.
  • Strong verbal and written communication skills for conveying complex information.
  • Effective problem-solving and decision-making abilities to address challenges and optimize training outcomes.
  • Ability to build and maintain relationships with physicians, commercial partners, regulatory bodies, and other stakeholders.
  • Proficiency in managing multiple projects simultaneously and ensuring their timely and successful completion.
  • Capacity to adapt to changing environments and incorporate new technologies and methodologies into training programs.
  • Commitment to ongoing professional development and staying current with industry trends and best practices.
  • A master's degree in business administration, health policy, health economics, life sciences, or healthcare; extensive relevant experience may be considered instead.
  • At least 15 years of biotechnology, pharmaceutical, or medical-device industry experience in professional affairs and medical education or another related function.
  • Ability to perform the stated physical demands, with reasonable accommodations available upon request.
  • Ability to work in a team-oriented, fast-paced environment.
Responsibilities
  • Lead, mentor, and develop a global team of leaders, including directors and regional education heads, while fostering a high-performance culture and leadership pipeline.
  • Own and define the global professional education strategy, including long-term vision, enterprise priorities, and investment allocation.
  • Translate business strategy into a scalable global education framework and operating model.
  • Define and lead the global key opinion leader engagement strategy, including identification, development, and activation of key opinion leaders.
  • Represent BD in global forums, congresses, and scientific collaborations.
  • Drive innovation in education delivery models, including digital, simulation-based, and data-driven approaches.
  • Establish global governance, key performance indicators, and performance metrics to assess effectiveness, adoption, and business impact across regions.
  • Oversee global budget governance, resource allocation, and standardized systems and tools.
  • Develop and implement evaluation and feedback mechanisms to assess and enhance educational initiatives.
  • Ensure educational programs adhere to industry standards, regulatory requirements, and best practices in medical education.
  • Provide strategic oversight of global education programs, ensuring alignment with global standards, scalability, and impact.
  • Align and manage online and in-person courses and programs.
  • Advise on and drive innovative strategies and priorities using practitioner and industry insights to advance BD product success through stakeholder engagement and medical education and training delivery.
  • Collaborate with Medical Affairs Operations to set strategic metrics for standard systems and tools, budgets, resource needs, processes, and training across Professional Education to drive operational excellence.
Desired Qualifications
  • An MBA, PhD, MD, or PharmD is preferred.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 Q3 revenue rose 5.4% and free cash flow 44.6%.
  • Management raised fiscal 2026 guidance after first post-spin quarter, signaling cleaner growth and stronger execution.
  • Brazil’s semaglutide launches and GLP-1 demand expand BD’s drug-delivery royalty-like platform opportunities.

What critics are saying

  • FDA recall on June 6, 2026 hits ChloraPrep sterility; infection claims threaten trust and hospitals.
  • July 31, 2026 intraosseous needle recall followed 75 complaints, 45 serious injuries, and four deaths.
  • Repeated recalls expose BD’s quality systems; one catastrophic medtech failure can trigger lawsuits and hospital switching.

What makes Becton Dickinson unique

  • BD’s all-in-one CentroVena One simplifies central lines, cutting steps 30% on June 23, 2026.
  • BD’s Vystra pen platform powers EMS’s July 29, 2026 semaglutide launch in Brazil.
  • BD’s July 9, 2026 CIRSE fellowship embeds clinicians inside its interventional ecosystem across five countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.

AMS Group, LLC
Aug 1st, 2026
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access.

Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access. July 31 (Reuters) - Becton Dickinson said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users reported difficulty in removing a part of the device after using it on patients. Here are some details: - The product, called an intraosseous needle set, is used to deliver fluids and medicine quickly into a patient's bone when a regular IV line cannot be used fast enough. This is often done in emergencies, such as cardiac arrest or severe trauma. - Becton said the issue involves a part called the obturator, or stylet, which sometimes cannot be removed after the needle is inserted. - The company said this incident can happen if the drill used to insert the needle is not pulled straight back, or if the obturator is rotated the wrong way when taken out. - As of June 2026, BD said it had received 75 complaints and 45 reports of serious injury related to the problem. The company also said four patients died when the part could not be removed during resuscitation efforts for people who had suffered cardiac arrest outside a hospital. - The affected needle sets were made with parts slightly out of the normal size range and were shipped between September 30, 2024, and June 12, 2026. - The recall does not include the intraosseous powered driver, which is the tool used to insert the needles. - BD said that if the obturator cannot be removed, medical staff may need to get a new needle or switch to another way of giving treatment, like a peripheral IV catheter. That delay could be dangerous, especially for critically ill patients, the company said. - The U.S. Food and Drug Administration has been informed about the recall, BD said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)

Life Sciences BC
Jul 29th, 2026
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch.

EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch. July 29, 2026 Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. * FRANKLIN LAKES, N.J. and SÃO PAULO - BD (Becton, Dickinson and Company) a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes. Global demand for GLP-1 therapies has highlighted the critical need for delivery systems that enable safe, accurate, and consistent dosing for patients. Many patients face challenges with ease of use, confidence with self-injection and adherence to treatment, making intuitive and reliable delivery solutions increasingly important. EMS's semaglutide utilizes BD's established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra(TM) Injection Pen platform reflects BD's deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies. "BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection." "Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS. "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X or Instagram @becton_dickinson. About EMS EMS is one of Brazil's leading pharmaceutical companies, with more than 60 years of experience developing and delivering innovative, high-quality therapies. The company operates across prescription medicines, generics and OTC, with a growing global footprint spanning more than 60 countries. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies for obesity and type 2 diabetes. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company) Original source here.

PR Newswire
Jul 29th, 2026
BD and EMS launch semaglutide GLP-1 therapy in Brazil for diabetes and obesity treatment

BD and EMS have launched a semaglutide therapy in Brazil to expand access to GLP-1 treatments for obesity and type 2 diabetes. The collaboration addresses growing demand for metabolic disease therapies whilst tackling patient challenges with self-injection and treatment adherence. EMS's semaglutide uses BD's Vystra injection pen platform, which features an intuitive design aimed at improving ease of use for patients. The pen platform reflects BD's expertise in drug delivery systems and supports scalable solutions to meet rising demand for injectable therapies. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. EMS operates across more than 60 countries and continues investing in advanced manufacturing and peptide capabilities.